Skye Bioscience, Inc. Common Stock (SKYE NASDAQ) stock market data APIs
$1.9814
0.25(12.6%)
as of May 5, 2025
Skye Bioscience, Inc. Common Stock Financial Data Overview
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Prev. Close
1.9814
Open
2.231
High
2.3026
Low
1.9948
52 wk Range
1.14-13.49
Market Cap
61 639 K
Shares Outstanding
30 975 K
Beta
1.75
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Skye Bioscience, Inc. Common Stock data using free add-ons & libraries
Get Skye Bioscience, Inc. Common Stock Fundamental Data
Skye Bioscience, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -29 896 278
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Skye Bioscience, Inc. Common Stock News
New
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metaboli...
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ah...
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ...
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
